Immunovant, Inc.
NASDAQ Global SelectTotal Valuation
Immunovant, Inc. carries a market capitalization of 8.10B, placing it among publicly traded companies globally. Its enterprise value stands at 7.15B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 8.10B |
| Enterprise Value | 7.15B |
Share Statistics
Immunovant, Inc. currently has 206.26M shares outstanding.
| Shares Outstanding | 206.26M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
| PE Ratio | N/A |
| PS Ratio | N/A |
| PB Ratio | 10.81 |
| P/TBV Ratio | 10.81 |
| P/FCF Ratio | -17.77 |
| P/OCF Ratio | -17.77 |
Financial Position
Immunovant, Inc. maintains a current ratio of 7.27, meaning it holds 7.3x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 7.27 |
| Quick Ratio | 6.82 |
| Debt / Equity | N/A |
| Debt / EBITDA | N/A |
| Interest Coverage | N/A |
Financial Efficiency
| Return on Equity (ROE) | -80.10 |
| Return on Assets (ROA) | -71.10 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Taxes
| Income Tax | -698,000.00 |
| Effective Tax Rate | N/A |
Stock Price Statistics
Immunovant, Inc.'s stock has gained approximately 143.48635% over the past 52 weeks. The 50-day moving average sits at 40.42, while the 200-day moving average is 30.48.
| Beta (5Y) | N/A |
| 52-Week Price Change | 143.48635% |
| 50-Day Moving Average | 40.42 |
| 200-Day Moving Average | 30.48 |
| Average Volume (20 Days) | N/A |
Income Statement
EBITDA reached -565.61M, while operating income came in at -566.00M.
| Revenue | N/A |
| Gross Profit | N/A |
| Operating Income | -566.00M |
| Pretax Income | -538.91M |
| Net Income | -538.22M |
| EBITDA | -565.61M |
| EBIT | -566.00M |
| Earnings Per Share (EPS) | -2.82 |
Balance Sheet
Total book value stands at 735.39M, with working capital of 734.08M providing operational flexibility.
| Cash & Cash Equivalents | 797.80M |
| Total Debt | N/A |
| Net Debt | -797.80M |
| Equity (Book Value) | 735.39M |
| Book Value Per Share | 3.57 |
| Working Capital | 734.08M |
Cash Flow
Immunovant, Inc. produced -414.30M in operating cash flow over the past twelve months. After subtracting -8,000.00 in capital expenditures, free cash flow totaled -414.31M - equivalent to -2.17 per share.
| Operating Cash Flow | -414.30M |
| Capital Expenditures | -8,000.00 |
| Free Cash Flow | -414.31M |
| FCF Per Share | -2.17 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | -7.71 |
| FCF Yield | -5.63 |
Scores
Immunovant, Inc. posts an Altman Z-Score of 36.45, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 36.45 |